| Document |
Document Title |
|
WO/2013/054302A1 |
The invention relates to a method for preparing a derivative of formula (I): (A)3-Bi, where the A groups, identical or different, are an aryl or heteroaryl radical, optionally substituted by at least one FG group, which can occupy any po...
|
|
WO/2013/050460A1 |
The present invention relates to ethynyl derivatives of formula I wherein Y is N or CH; with the proviso that Y can only be CH, if at least on of U, V or W are N; U is N or C-R4; V and W are independently N or CH; with the proviso that o...
|
|
WO/2013/050421A1 |
The present invention provides a compound of Formula (I) or an agronomically acceptable salt thereof, wherein:R2 is selected from the group consisting of (A1), (A2) and (A3) wherein X1 is N or CR7 X2 is N or CR8 X3 is N or CR9 X4 is N or...
|
|
WO/2013/037753A1 |
The present invention relates to novel non-steroidal brassinosteroid mimetic derivatives, to processes and intermediates for preparing them, to plant growth regulator compositions comprising them and to methods of using them for controll...
|
|
WO/2013/035827A1 |
The purpose of the present invention is to provide: a novel compound which is represented by formula (I') and has ACC2 inhibitory activity; and a medicinal composition which contains the compound. (In the formula, R1 represents a substit...
|
|
WO/2013/030205A1 |
The present application disclosed compounds of Formula I wherein variables R1 and R2 are defined as described herein, which are inhibitors of PARP and provides compounds and compositions containing the compounds of Formula I. The present...
|
|
WO/2013/029338A1 |
Disclosed are novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.
|
|
WO/2013/027660A1 |
A novel pesticide is provided. The present invention provides a compound represented by the formula (I) or its salt: wherein Q is phenyl or pyridyl which may be substituted; W is an oxygen atom or S(O)m; each of A1 to A5 is -C(R5)= or a ...
|
|
WO/2013/027000A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them an...
|
|
WO/2013/019938A1 |
Pyridazine derivatives that activate the excitatory amino acid transporter 2 (EAAT2), and methods of use thereof for treating or preventing diseases, disorders, and conditions associated with glutamate excitotoxicity.
|
|
WO/2013/005157A1 |
Provided herein is novel compound of the general formula (I), its tautomeric forms, its stereoisomers, its analogs, its prodrugs, its isotopes, its N- oxides, its metabolites, its pharmaceutically acceptable salts, its polymorphs, its so...
|
|
WO/2012/173983A1 |
Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
|
|
WO/2012/165648A1 |
The present invention provides a compound having an excellent efficacy for controlling weeds. A cyclohexanone compound of the formula (I): wherein m is an integer of 1, 2 or 3; n is an integer of any one of 1 to 5; X represents CH2, O, S...
|
|
WO/2012/162254A1 |
The present invention provides compounds having a structure according to Formula I: (I) or a salt or solvate thereof, wherein R1, R2, R3 and R4 are defined herein. The invention further provides pharmaceutical compositions including the ...
|
|
WO/2012/158200A1 |
Provided is a macromolecule comprising two or more functionalized bis-peptides connected by one or more linkers, and methods of making thereof. In some embodiments, the functionalized bis-peptides are covalently attached to one or more f...
|
|
WO/2012/155199A1 |
The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the tr...
|
|
WO/2012/158399A1 |
Disclosed herein are KCNQ potassium channels modulators of formula (I) wherein ring G1, R1, and R2 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such ...
|
|
WO/2012/154760A1 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
WO/2012/141604A1 |
The invention relates to the new, asymmetrically substituted derivatives of 2,7-dihydro-3H-dibenzo[de,h]cinnoline-3,7-dione and their use as cytostatics exhibiting activity against tumor cells, especially against cells with multidrug res...
|
|
WO/2012/136703A1 |
The present invention relates to novel herbicidal compounds of Formula (I), or an agronomically acceptable salt of said compound wherein R1, R2, A1, Ra, Rb, Rc and Rd are as defined herein. The invention further relates to compositions w...
|
|
WO/2012/130137A1 |
The present invention discloses an aryloxy dihalopropenyl ether compound with the structure shown as general formula (I), of which the group definitions can be seen in the specification. The present invention also discloses the use of th...
|
|
WO/2012/126570A1 |
The invention relates to combinations having at least one bicyclic or tricyclic ring system, which is connected by acetylene ethylene or difluoroethylene bridges, to the application thereof in high frequency components, to liquid crystal...
|
|
WO/2012/124696A1 |
[Problem] To provide a compound which is useful as an active ingredient of a pharmaceutical composition, especially of a pharmaceutical composition for the prophylaxis and/or treatment of VAP-1 associated diseases. [Solution] As a result...
|
|
WO/2012/120195A1 |
The invention relates to pyridazinone and pyridone com- pounds having formula (I) or (I'), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1 / R4 and X and X3 are as defined in the claims. The invention...
|
|
WO/2012/120398A1 |
The invention provides a compound of the formula (I): wherein A, R1, R2 and R3 are as defined herein, or a pharmaceutically acceptable salt thereof. Such compounds are small molecule TRPM8 blockers and therefore useful in the propylaxis ...
|
|
WO/2012/119045A2 |
Hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, compositions comprising hydrazinopyridazines, fused hydrazinopyridazines, phenylethylhydrazines, or combinations thereof, and methods for u...
|
|
WO/2012/097682A1 |
The present invention relates to compounds of formula (1) or pharmaceutical acceptable salts, wherein R1, X, Y, Z, A, B, G1, and n are defined in the description. The present invention relates also to compositions containing said compoun...
|
|
WO/2012/091156A1 |
The present invention relates to a pyridazinone compound of the formula (I): wherein R1 represents hydrogen, a C1-6 alkyl group, and the like, R2 represents halogen, a cyano group, a nitro group, a C1-6 alkoxy group, and the like, G repr...
|
|
WO/2012/085001A1 |
The present invention relates to diarylpyridazinone derivatives that block the potassium Kv channels (specifically the Kv1.5, Kv4.3, and Kv11.1 channels) and to the use thereof for the treatment of humans. Said compounds have the general...
|
|
WO/2012/082857A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. I...
|
|
WO/2012/082853A1 |
In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In an...
|
|
WO/2012/072033A1 |
Provided are substituted 2,3-phthalazinone compounds, their isomers, salts, solvates, prodrugs, their preparation and the use for the preparation of medicaments for inhibiting the activity of poly (adenosine diphosphate-ribose) polymeras...
|
|
WO/2012/062412A1 |
Tanned leather, skin or pelt is produced by non-metal tanning, comprising the step of tanning a bated hide, skin or pelt with a tanning agent (A), the tanning agent (A) being a sulpho-group-containing dichloro-diazine selected from compo...
|
|
WO/2012/050041A1 |
The present invention provides a pest control agent, an acaricide, or a bactericide that contains, as the active ingredient thereof, at least one type of compound selected from aryloxyurea compounds represented by formula (V) (wherein R1...
|
|
WO/2012/048258A2 |
The new pyridazine derivatives have unexpected drug properties as inhibitors of protein kinases especially against c-Met and are useful in treating disorders related to abnormal protein kinase activities such as cancer.
|
|
WO/2012/038942A1 |
This invention also relates to pharmacological compositions containing the compounds of the present invention, and methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonar...
|
|
WO/2012/037132A1 |
JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating dise...
|
|
WO/2012/037258A1 |
The present invention relates to processes for preparing enantiomerically pure cyclopropyl amine derivatives and salts thereof; the chiral intermediates such as the chiral salts are useful for the preparation of such chiral compounds and...
|
|
WO/2012/031383A1 |
Compounds of general formula (I) and pharmaceutically acceptable salts thereof are disclosed, in which R1, R2, R3, R4, R5 and Ar are defined as in the description.
|
|
WO/2012/033225A1 |
The present invention relates to a novel method for producing a pyridazinone compound and an intermediate thereof as shown in the following scheme: wherein the symbols are as defined in the specification.
|
|
WO/2012/029672A1 |
The present invention relates to amine derivatives each represented by chemical formula (I) (wherein Ar represents a phenyl group or the like; R1 represents a hydrogen atom or the like; R2 represents a C1-6 alkylcarbonyl group or the lik...
|
|
WO/2012/028629A1 |
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by LRRK2 kinase activity, f...
|
|
WO/2012/025450A1 |
New phenylamidines are described, having general formula (I) and their use for the control of phytopathogenic fungi.
|
|
WO/2012/020742A1 |
Disclosed is a novel compound that acts as an antagonist for P2X3 and/or P2X2/3 receptors. Also disclosed is a pharmaceutical composition that acts as an antagonist for P2X3 and/or P2X2/3 receptors, said composition containing: a compoun...
|
|
WO/2012/014221A1 |
Disclosed are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-r...
|
|
WO/2012/013728A1 |
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a...
|
|
WO/2012/014963A1 |
[Problem] To provide a compound which can act relying on an agonistic activity on cannabinoid receptor type 2 and is therefore useful as a novel and excellent prophylactic and/or therapeutic agent for diseases associated with cannabinoid...
|
|
WO/2012/011081A1 |
The invention relates to compounds of formula (I): in which: n is equal to 0 or 1; D represents an oxygen atom or a bond; W represents a nitrogen atom or a -CH- group; X1 represents a nitrogen atom or a -CH=CH- group; X2 represents an ox...
|
|
WO/2012/004743A1 |
The invention relates to sulfonamide derivatives, to their use i n medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new ...
|
|
WO/2012/003748A1 |
Disclosed are a kind of N-oxo-aryloxyphenoxycarboxylic acid amide compounds, preparation method and application thereof. The said N-oxo-aryloxyphenoxycarboxylic acid amide compounds are shown by formula (I), in which R1 is H or C1-C3 alk...
|
